Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Taylor Monson
Observed names:
Taylor E Monson,
Taylor E. Monson
Institution:
The University of Kansas Cancer Center
Observed institutions:
Nebraska Medical Center,
The University of Kansas Health System,
The University of Kansas Cancer Center,
University of Nebraska Medical Center
ORCID:
0000-0003-0369-6149
Observed ORCID:
0000-0003-0369-6149
OpenAlex ID:
A5015460838
Randomized Trial of Fixed-Dose Capecitabine Compared With Standard-Dose Capecitabine in Metastatic Breast Cancer: X-7/7 Trial
2025
·
Qamar J. Khan
, Colleen Bohnenkamp
, et al.
·
JCO oncology advances.
·
16
Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial.
2023
·
Qamar J. Khan
, Colleen Bohnenkamp
, et al.
·
Journal of Clinical Oncology
·
13
Olanzapine as a rescue antiemetic in hematopoietic stem cell transplant
2019
·
Taylor Monson
, Devon Greer
, et al.
·
Journal of Oncology Pharmacy Practice
·
5
Real-World Outcomes of Abemaciclib Dose-Escalation Strategy in High-Risk Early Breast Cancer
2026
·
Noor Lad
, Sarah Blocker
, et al.
·
Clinical Breast Cancer
·
1
Comparison of pembrolizumab dosing regimens and incidence and severity of immune-related adverse effects: A retrospective, case-control study
2026
·
Taylor E Monson
, Vincent J Cascone
, et al.
·
American Journal of Health-System Pharmacy
Standard-dose vs fixed-dose capecitabine in patients with advanced gastrointestinal and metastatic breast cancer.
2025
·
Nanuli Gvazava
, Qamar J. Khan
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
6
Citation count:
35
H-index:
3
I10-index:
2
Year
Topic
Type